RAM
RCUS icon

Readystate Asset Management’s Arcus Biosciences RCUS Stock Holding History

Readystate Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-351,356
Closed -$5.23M – 718
2024
Q4 		$5.23M Buy
+351,356
New +$5.74M 0.16% 138

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Readystate Asset Management's RCUS Position: Q1 2025 in Review

Readystate Asset Management sold out of Arcus Biosciences (RCUS) in Q1 2025, closing a stake of 351,356 shares — an estimated $5.23M sold.

Readystate Asset Management first reported a position in RCUS in Q4 2024 and held it in 1 quarter. The position peaked at $5.23M in Q4 2024. 186 funds tracked by Wall St. Rank hold RCUS as of Q1 2025.

  • Readystate Asset Management reported no remaining Arcus Biosciences position as of Q1 2025 after selling out during the quarter.
  • Readystate Asset Management sold 351,356 Arcus Biosciences shares in Q1 2025, an estimated $5.23M.
  • Readystate Asset Management first reported a position in Arcus Biosciences in Q4 2024 and held it in 1 quarter.
  • Readystate Asset Management's Arcus Biosciences position peaked at $5.23M in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2025.

Based on Readystate Asset Management's 13F filing for Q1 2025, filed 6 May 2025.